Skip to content 
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts. more
| Dec '24 | Dec '25 | |||||
|---|---|---|---|---|---|---|
| Total Revenue | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Cost of Revenue | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Gross Profit | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Gross Margin | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Operating Expenses | 50.38M | 70.12M | [{"date":"2024-12-31","value":71.85,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |||
| Operating Income | (50.38M) | (70.12M) | [{"date":"2024-12-31","value":-5038300000,"profit":false},{"date":"2025-12-31","value":-7011900000,"profit":false}] | |||
| Total Non-Operating Income/Expense | 1.86M | 5.98M | [{"date":"2024-12-31","value":31.13,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |||
| Pre-Tax Income | (48.52M) | (64.14M) | [{"date":"2024-12-31","value":-4852200000,"profit":false},{"date":"2025-12-31","value":-6414000000,"profit":false}] | |||
| Income Taxes | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Income After Taxes | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Income From Continuous Operations | (48.71M) | (63.91M) | [{"date":"2024-12-31","value":-4870700000,"profit":false},{"date":"2025-12-31","value":-6391300000,"profit":false}] | |||
| Income From Discontinued Operations | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Net Income | (48.71M) | (63.91M) | [{"date":"2024-12-31","value":-4870700000,"profit":false},{"date":"2025-12-31","value":-6391300000,"profit":false}] | |||
| EPS (Diluted) | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| COAG | |
|---|---|
| ROA (LTM) | -30.11% |
| ROE (LTM) | -46.99% |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| COAG | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 0.00 |
| EV/R | 0.00 |
| EV/Ebitda | NM |
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) share price today is $28.07
Yes, Indians can buy shares of Hemab Therapeutics Holdings, Inc. Common Stock (COAG) on Vested. To buy
Yes, you can purchase fractional shares of Hemab Therapeutics Holdings, Inc. Common Stock (COAG) via the Vested app. You can start investing in Hemab Therapeutics Holdings, Inc. Common Stock (COAG) with a minimum investment of $1.
You can invest in shares of Hemab Therapeutics Holdings, Inc. Common Stock (COAG) via Vested in three simple steps:
The 52-week high price of Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is $36.61. The 52-week low price of Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is $18.
The price-to-earnings (P/E) ratio of Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is
The price-to-book (P/B) ratio of Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is 0.00
The dividend yield of Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is 0.00%
The market capitalization of Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is $1.33B
The stock symbol (or ticker) of Hemab Therapeutics Holdings, Inc. Common Stock is COAG
Consider the share price of Hemab Therapeutics Holdings, Inc. Common Stock as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Hemab Therapeutics Holdings, Inc. Common Stock has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Hemab Therapeutics Holdings, Inc. Common Stock shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Hemab Therapeutics Holdings, Inc. Common Stock stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Hemab Therapeutics Holdings, Inc. Common Stock and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Hemab Therapeutics Holdings, Inc. Common Stock stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
